Dear Colleagues,

Thank you so much for placing your trust in me. As my term comes to a close, I have reflected on all that we have accomplished together over the past two years. It has been the honor of a lifetime to serve as chair of the AANS/CNS Section on Tumors, founded in 1984 by my mentor at Henry Ford, Mark Rosenblum, MD, FAANS(L). I have been blessed with incredible role models in my neurosurgical career thus far; my predecessor as Tumor Section chair, Fred G. Barker II, MD, FAANS, led us into a new era of unprecedented growth and relevance in organized neurosurgery. Fred was also one of my earliest tumor mentors when I trained at the MGH. I also know that I am leaving the Section in the most capable and enthusiastic hands, as Manish Aghi, MD, PhD, FAANS, will champion the cause of our Section and our profession and lead us to even greater heights. Indeed, mentorship serves as a powerful and enduring bond among all of us who pursue the calling of neurosurgery.

Many of our strategic initiatives over the past two years focused intensely on transforming the Section into a beacon of mentorship, innovation and best-practice expertise for our growing worldwide membership.

Together, thanks to YOUR leadership:

- We expanded overall Section membership – including international partners – by 10 percent at a time when membership in professional societies and meeting attendance are dropping and we have increased our treasury to an all-time high in order to sponsor more fellowships and educational outreach.
- In 2016, we hosted a remarkable Satellite Symposium in San Diego, which broke all prior attendance records while honoring multiple luminaries in our field. We focused on the management of low grade gliomas, with three keynote speakers, Mitchel Berger, MD, FAANS; Hugues Duffau, MD; and Jim Rutka, MD, PhD, FAANS, all world-renowned pioneers in the management of low grade gliomas and multi-modality, maximal safe resection. We are looking forward to another phenomenal Satellite meeting this October in Houston as well.
- We assembled a spectacular line-up of practical courses, seminars and special scientific program offerings at multiple national meetings. Thanks goes to the incredible efforts of our program chairs, Chetan Bettegowda, MD, FAANS; Brian Nahed, MD; Ian Lee, MD, FAANS; Ekkehard Kasper, MD, PhD, FAANS; Pamela Jones, MD, MPH; Adam Robin, MD; Shawn Hervey-Jumper, MD, FAANS; and Peter Fecci, MD. All of these program chairs worked closely with our Section Scientific Program Chair Jason Sheehan, MD, PhD, FAANS, who, in this new role, coordinated a phenomenal Satellite meeting this October in Houston as well.
- In the spirit of mentorship and service, we launched a brand new Tumor Section mentorship award named in honor of the late Andy Parsa, MD, PhD, and we renamed our Distinguished Service Award in honor of our founder, Dr. Rosenblum.
- In the spirit of mentorship and service, we launched a brand new Tumor Section mentorship award named in honor of the late Andy Parsa, MD, PhD, and we renamed our Distinguished Service Award in honor of our founder, Dr. Rosenblum.
- We have continued the time honored traditions of our Young Neurosurgeon’s mentoring reception under the enthusiastic leadership of Walavan Sivakumar, MD, and the Bittner (Russ Lonser, MD, FAANS, and Dr. Rosenblum) and Guha (Fred Lang, MD, FAANS) awards as well in partnership

Continued on the next page >>
Chair’s Message Continued

with the Society for Neuro-oncology.

• Thanks to the herculean efforts of Awards Chair Isabelle Germano, MD, FAANS, and her awards team, we have distributed a record number of grants, fellowships and honors to young neurosurgeons ready to start their careers in neurosurgical oncology, including the BrainLab, Journal of Neuro-oncology, ABTA, Preuss, Stryker Neuro, Integra, Synthes Skullbase and Columbia Softball Pediatric Brain Tumor awards. I am also pleased to announce that our three section-based NREF Honor Your Mentor funds (Parsa, Wilson, Rutka) now have a combined value of over $1M and offer additional opportunities for the Section to impact the careers of young neurosurgeons. In addition to the traditional Tumor Section fellowships, we launched two new $50,000 fellowship awards: the Andrew Parsa Research Award and the BCured – Tumor Section Award.

• Tumor Guidelines, under the leadership of Jeff Olson, MD, FAANS, and Brian Nahed, MD, powered most of the guidelines effort for all of organized neurosurgery, with incredible productivity from our tumor author groups. Over the past two years alone, we have produced guidelines in pituitary adenoma, vestibular schwannoma, low grade glioma, spinal metastases and updates on malignant gliomas and brain metastases.

• A powerful new social media initiative was launched on Facebook, LinkedIn and Twitter (@NSTumorSection), thanks to Edjah Nduom and his team. Within 48 hours of the launch, over 250 members and potential future tumor section members had already signed up, including from places like Brazil, Nigeria, Myanmar, Australia and nearly everywhere in between. We believe this significant enhancement in our digital connectivity, combined with our brand new website re-design at http://www.tumorsection.org launched and updated by Jeff Weinberg, MD, FAANS, and his team will significantly increase the reach, and relevance, of the Tumor Section for years to come.

• Last year, Costas Hadjipanayis, MD, PhD, FAANS, and I had the honor of testifying before the Food and Drug Administration Medical Imaging Drugs Advisory Committee and achieved unanimous approval for the use of 5-ALA as an imaging agent to facilitate the real-time detection and visualization of malignant tissue during glioma surgery. Dr. Hadjipanayis served as the lead study investigator and has been working tirelessly for many years, along with Walter Stummer, MD, PhD, from Germany, to provide evidenced based support for the use of 5-ALA in the United States. In fact, many in the Tumor Section participated in training sessions and the national multi-institutional clinical trial led by Isabelle Germano, MD, FAANS, to study efficacy and positive predictive value of 5-ALA.

• Thanks to Ric Komotar, MD, FAANS, and his team, we nearly doubled the size of our international committee to include representatives from every continent and major world society.

• We expanded our membership outreach under committee chair Jen Moliterno Gunel, MD, FAANS, and customized program offerings thanks to Randy Jensen, MD, PhD, FAANS; Ron Warnick, MD, FAANS; Isaac Yang, MD, FAANS; Orin Bloch, MD; and Jason Sheehan, MD, PhD, FAANS, who launched new membership surveys to help guide the course of our field through best practice paradigm development.

• Our development efforts have never been more successful thanks to Will Curry, MD, FAANS, and his team. This has powered much of our programmatic offerings over the past two years, including more robust relationships with industry awards as well, led by Andy Sloan, MD, FAANS.

• My hope is that our focus on new academic career advising activities for young neurosurgeons in terms of how to start a practice, set up a lab, apply for grants, maximize protected time, negotiate contracts and become more involved in organized neurosurgery, as well as expanding our Young Neurosurgeons events at the annual meetings, will carry our profession and the Tumor Section ever higher in the years and decades to come. I especially want to thank our entire Executive Committee, listed on the back page of this newsletter, for their service, commitment and enthusiasm over the past two years. I must also thank our newsletter editors, Drs. Ian Lee and Pamela Jones, for producing the most expansive and most widely distributed newsletters in our history.

It is now my honor to formally welcome and congratulate Dr. Manish Aghi on his new role!

I’m looking forward to seeing everyone in New Orleans.

Onward and upward,

Steven N. Kalkanis, MD, FAANS
Chair, Section on Tumors
The 2018 AANS Annual Scientific Meeting is shaping up to be an exciting event! Our members have had many invaluable suggestions related to improving the educational content of both our scientific sessions and seminars. One of the suggestions was to incorporate spinal neuro-oncology into our program as this had not been a focus in recent years.

To that end, we devote one of our scientific sessions to the spine and expect this to be educational and stimulating for both the general and subspecialty neurosurgeon. We will hear presentations given by experts in the field including Drs. Ziya Gokaslan, Mark Bilsky, Claudio Tatsui, Laurence Rhines, Jason Sheehan and Nick Szerlip. These discussions will cover up-to-date material for management of primary and metastatic spinal tumors. Additionally, the presentations will be followed by an interactive panel discussion simulating a Spine Tumor Board with audience polling.

Our second scientific session relates to viral oncolytic therapy in glioma. The last decade has seen tremendous scientific progress made in designing viruses for oncolytic purposes, with many phase 2/3 trials underway. To put this all in perspective, showcase its promise, describe its limitations and point the way forward – we have assembled a stellar group. These luminaries include Drs. Robert Martuza, Nino Chiocca, Fred Lang, James Markert and special guest Juan Fueyo. We expect this to be a tremendous scientific exchange.

Finally, there are a number of new and updated Breakfast Seminars and Practical Clinics being offered this year. Topics include general updates in the management of gliomas, thoughtful discussions about the management of skull base lesions, the role of laser interstitial thermal therapy, the role of fluorescence-guided surgery and many more. Please check out the 2018 AANS Annual Scientific Meeting online program here for more information. See you in New Orleans!
CNS 2018

Gordon Li, MD, FAANS; Seunggu Han, MD

We are excited to see everyone at the Congress of Neurological Surgeons annual meeting this year. The Tumor Section is putting together an exciting agenda full of international expert surgical neuro-oncologists. The topics of the two main tumor sessions will cover contemporary management and guidelines for incidentally found tumors and technological advances in adjuncts to brain tumor surgery. We have a number of practical course covering topics from 3-D surgical anatomy to modern applications of radiosurgery and surgical management of eloquent brain tumors. Lunch seminars include current management strategies for acoustic neuromas as well as cutting-edge management in brain metastases.

CNS 2017

Pamela Jones, MD, MPH; Adam Robin, MD

The 2017 CNS Annual Meeting was an unmitigated success. Themed Transformation & Celebration, concepts that challenge traditional neurosurgical paradigms were presented and reviewed by luminaries in our field.

Drs. Brooke Swearingen, Jason Sheehan and Edward Laws moderated our first Tumor Session, focused on the first comprehensive guidelines for the management of non-functioning pituitary adenomas and supported by the AANS/CNS Section on Tumors. Drs. Paul Gardner, Ian Dunn and Gabriel Zada went on to further explore and review the guidelines, the genetics of adenoma and modern techniques used in surgery for pituitary tumors. The presentation of oral abstracts were amongst the most illuminating in recent years.

Breaking with a century of tradition, the 2016 World Health Organization Classification on Tumors of the Central Nervous System recently moved beyond a system based largely on tissue evaluation under a microscope to a hybridized classification, incorporating molecular data. Drs. Maria Martinez-Lage Alvarez, Bob Carter and Fred Lang helped us to understand the new classification system, its prognostic and predictive value and updated us on current clinical trials and targeted therapies for glioma.

The CNS 2017 program also featured a variety of dinner seminars on the contemporary management of skull base tumors as well as interactive breakout sessions. More than a dozen tumor-focused practical courses and luncheon seminars were well-attended, including a program spotlighting new clinical trials directed by Dr. Michael A. Vogelbaum.

We hope you enjoyed celebrating with us the many accomplishments of neurosurgeons from around the world!
The 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) took place November 16-19, 2017, in San Francisco. Manish Aghi, MD, PhD, FAANS, was one of the scientific directors of the meeting and was also instrumental in the organization of the local events. Nino Chiocca, MD, PhD, FAANS, completed his term as president of the society with Patrick Wen, MD, assuming the position.

There continues to be strong involvement of Tumor Section members in leadership positions, either as an officer or on the SNO Board of Directors. These include Gelareh Zadeh, MD, PhD, FAANS (vice president); Ian Dunn, MD, FAANS (neurosurgery representative); Michael Taylor, MD, PhD (basic science representative); and Mitchel Berger, MD, FAANS (member of the SNO Foundation Board).

Across the meeting, the Cancer Moonshot Project was broadly featured and included a keynote presentation from W. K. Alfred Yung, MD, that highlighted areas where neuro-oncology plays a pivotal role within the 10 Blue Ribbon Panel priority areas for accelerating progress in cancer. In addition, the SNO Education Day focused on three Cancer Moonshot recommendations: overcome therapeutic resistance, minimize side effects of cancer treatments and develop new cancer technologies.

A few of the many important scientific presentations at this year’s meeting highlighted the results of therapeutic clinical trials that spanned diverse approaches to treatment that included tumor-specific antibody-drug conjugates (depatux-m), an autologous formalin-fixed tumor vaccine, intensive combinations of standard alkylating chemotherapy agents in promotor methylated O6-methylguanine-DNA methyltransferase glioblastoma, retroviral replicating vector Toca 511 and inhibitors of isocitrate dehydrogenase 1.

On the basic and translational science side, highlights included presentations on the mechanism of alternative telomere lengthening in IDH mutated tumors, modulation of the transcription of oligodendrocyte transcription factor (OLIG2) target genes using a small-molecule inhibitor CT-179, molecular characterization of aggressive meningioma that identified Forkhead Box M1 as a prognostic marker and studies that demonstrated the importance of molecular classification of pediatric embryonal tumors in clinical trials.

The 2018 annual meeting will be held in New Orleans from November 15-18 and, if the pattern continues, we anticipate record-breaking abstract submissions and attendance numbers.
The Tumor Section Awards Committee continues to actively develop the most robust award program for outstanding research of any of the AANS/CNS sections. Each year, we give 12 awards, plus one named lectureship at the AANS Annual Scientific Meeting and nine awards, plus one lectureship every-other-year at the CNS meeting. Additionally, we offer three awards at our Biennial Tumor Satellite Symposia. Most of the awards are limited to Tumor Section members, which provides an additional incentive for membership.

The AANS/CNS Section on Tumors would like to thank the award sponsors for helping to encourage submissions of the highest quality work in neuro-oncology.

The Tumor Section nine CNS 2017 award winners and the Gupta Award lectureship, given at the CNS meeting, are shown below. Congratulations to each winner!

The section is looking forward to recognizing 12 award winners at the 2018 AANS Annual Scientific Meeting, as summarized in the table. Congratulations!

**Abhijit Guha Award and Lectureship**
Fred Lang, MD, FAANS, is the recipient of the 2017 Abhijit Guha Award for his numerous outstanding scientific contributions with clinical and research relevance in the field of brain tumors.

The Abhijit Guha Award and lecture are jointly sponsored by the Society of Neuro-Oncology (SNO) and it is given annually, alternating between the SNO and CNS meeting. The winner is a physician scientist making great strides in the laboratory and clinic.

**2018 CONGRESS OF NEUROLOGICAL SURGEONS AWARDEES**

**American Brain Tumor Association Young Investigator Award**
Arka Mallela, MD, is the 2017 recipient of the American Brain Tumor Association Award for the work entitled *Topical Vancomycin Reduces Surgical-site Infections After Craniotomy: A Prospective, Controlled Study*, presented during the Tumor Section Session I on Monday, October 9, 2017.

Sponsored by the American Brain Tumor Association, the Young Investigator Award is given at the AANS Annual Scientific and the CNS meetings to a young faculty member involved in neuro-oncology research and has demonstrated outstanding potential for future basic scientific research. The applicant must have been out of training for less than six years. A $2,000 honorarium accompanies this award.

**BrainLab Neurosurgery Award**
Adomas Bunevicius, MD, is the recipient of the 2017 BrainLab Neurosurgery Award that was presented at the CNS meeting for the work entitled: *Prognostic Role of the Low Tri-Iodothyronine Syndrome in Brain Tumor Patients*, presented during the Tumor Section Session I on Monday, October 9, 2017.
The BrainLab Neurosurgery Award is presented at the annual meetings of the AANS and CNS. This award is given to a neurosurgeon practicing in a nonacademic or international setting with the best abstract related to central nervous system tumors. Previous AANS/CNS Section on Tumors chairs Michael McDermott, MD, FAANS, and Ronald Warnick, MD, FAANS, were instrumental in securing this award, given through the generosity of BrainLAB. The award carries an honorarium of $1,000.

Columbia Softball Pediatric Brain Tumor Award
Hongwei Zang, MD, was the recipient of the 2017 Columbia Softball Charity Award for the work entitled: *Interaction Between MELK and EZH2 Regulates Medulloblastoma Cancer Stem-like Cells Proliferation*, presented during the Section on Tumor Session II on Tuesday, October 10, 2017.

The Columbia Softball Pediatric Brain Tumor Award is given to the best pediatric tumor abstract submitted by a resident or faculty member who is a member of the Tumor Section at each AANS/CNS meeting. The section would like to acknowledge previous Section Chairs Jeff Bruce and Fred Barker and Rich Anderson for putting together the plan to use a portion of the proceeds from the annual tournament to support this award. The award carries an honorarium of $1,000.

Integra Foundation Award
Matthew Agam, MD, is the recipient of the 2017 Integra Award for the presentation entitled: *Complications Associated with Transsphenoidal Pituitary Surgery: Experience of 1,171 Consecutive Cases Treated at a Single Tertiary Care Pituitary Center*, presented during the Section on Tumor Session I on Monday, October 9, 2017.

The Integra Foundation Award, sponsored by the Integra Foundation, is given at both the AANS and CNS meetings for the best research or clinical paper submitted that investigates benign brain, spinal or peripheral nerve tumors. The award carries an honorarium of $1,000.

Mahaley Clinical Research Award
Tareq Juratli, MD, was the recipient of the 2017 Mahaley Clinical Research Award for the presentation entitled: *TERT Promoter Mutations in Progressive Treatment-resistant Meningiomas*, presented during the Section on Tumor Session I on Monday, October 9, 2017.

The NBTS Mahaley Award is given at each of the AANS and CNS meetings to a neurosurgery resident, fellow or attending physician who submits the best clinical study in neuro-oncology. The award carries a $1,000 honorarium.

Preuss Young Scientist Award
Matthew Garrett, MD, PhD, was the recipient of the Preuss Young Scientist Award at the CNS 2017 meeting for the work entitled: *Metabolic Characterization of IDH1mutant and IDH Wildtype*
Gliomaspheres Uncovers Cell-type Specific Vulnerabilities, presented during the Section on Tumor Session II on Tuesday, October 10, 2017. Sponsored by the Preuss Foundation, the Preuss Young Scientist Award is given at each of the AANS and CNS meetings to a young scientist investigating brain tumors, within 10 years of training, and who has submitted the best basic science research paper. This award has a $1,000 honorarium.

The Springer Journal of Neuro-Oncology Award Desmond A. Brown, MD, PhD, was the recipient of the Springer Journal of Neuro-Oncology Award at the CNS 2017 meeting for the work entitled: Small Terminal Deletions/Duplications and Alternative Lengthening of Telomeres are Co-Occur in IDH Mutation Only Gliomas, presented during the Section on Tumor Session I on Monday, October 9, 2017.

The Springer Journal of Neuro-Oncology Award is presented at both the annual AANS and CNS meetings to a highly-ranked abstract in either clinical or basic science, as related to neuro-oncology. This award is sponsored by the generosity of Springer. This award carries a $1,000 honorarium.

Stryker Neuro-Oncology Award Suganth Suppiah, MD, was the recipient of the Stryker Neuro-Oncology at the 2017 CNS meeting for the presentation entitled: Genomic Landscape of Radiation-Induced Meningiomas, presented during the Section on Tumor Session I on Monday, October 9, 2017.

The Stryker Neuro-Oncology Award is given to a high-ranking brain tumor clinical or basic science abstract submitted by a resident or medical student. The award is presented at the CNS and AANS annual meetings and the senior author of the paper must be a member of the AANS/CNS Section on Tumors. This award carries a $1,000 honorarium. Moving forward this award is re-named as the AANS/CNS Joint Section on Tumors Neuro-Oncology Trainee Award.

Synthes Skull Base Award Fahad Alkherayf, MD, FAANS, is the recipient of the 2017 Synthes Skull Base Award for the presentation entitled: Reinventing the Wheel: Intraoperative Continuous Flash Visual Evoked Potentials, a Novel Technique to Lessen Intraoperative Optic Nerves and Chiasmal Injury in Endoscopic Skull Base Surgery, presented during the Section on Tumor Session I on Monday, October 9, 2017.

The Synthes Skull Base Award is given to an attending neurosurgeon, resident or fellow in the Tumor Section who submits the best abstract related to skull base surgery. This award is given at the annual meetings of the AANS and CNS. The award includes a $1,000 honorarium. Moving forward this award is re-named the AANS/CNS Joint Section on Tumors Skull Base Award.
Congratulations to the 2018 AANS Tumor Section Award Winners. Please join us for their presentations!

<table>
<thead>
<tr>
<th>Award</th>
<th>Awardee</th>
<th>Title</th>
<th>Date and Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integra Foundation Award</td>
<td>Andrew Scott Little, MD, FAANS</td>
<td>Prospective Multicenter Study Comparing Surgical Outcomes of Microscopic Transsphenoidal Surgery and Fully Endoscopic Transsphenoidal Surgery Techniques for Nonfunctioning Pituitary Adenomas (TRANSSPHER Study)</td>
<td>05/02/2018 12:34-12:44 p.m.</td>
<td>Plenary Session III</td>
</tr>
<tr>
<td>ABTA Young Investigator Award</td>
<td>Gautam Unmeel Mehta, MD</td>
<td>Repeat Stereotactic Radiosurgery for Cushing's Disease: Outcomes of an International, Multicenter Study.</td>
<td>05/01/2018 4:41-4:50 p.m.</td>
<td>AANS/CNS Section on Tumors I</td>
</tr>
<tr>
<td>AANS/CNS Joint Section on Tumors Skull Base Award</td>
<td>Soichi Oya, MD, IFAANS</td>
<td>Intraoperative Assessment of Meningioma Proliferative Potential Revealed Intratumoral Heterogeneity and Its Relevance to Biological Characteristics</td>
<td>05/01/2018 4:31-4:40 p.m.</td>
<td>AANS/CNS Section on Tumors I</td>
</tr>
<tr>
<td>Leksell Radiosurgery Award</td>
<td>Dale Ding, MD</td>
<td>Stereotactic Radiosurgery for the Management of Acromegaly: Outcomes of a Multicenter Retrospective Cohort Study</td>
<td>05/01/2018 4:21-4:30 p.m.</td>
<td>AANS/CNS Section on Tumors I</td>
</tr>
<tr>
<td>Brainlab Neurosurgery Award</td>
<td>Koray Ozduman, MD</td>
<td>Analysis of Mutational Processes in 23 Adult Hemispheric Diffuse Gliomas Identifies DNA-Damage Repair Deficiency as a Major Contributor to Gliomagenesis.</td>
<td>04/30/2018 3:10-3:19 p.m.</td>
<td>Scientific Session I: Tumor</td>
</tr>
<tr>
<td>Brian D. Silber Award</td>
<td>Anick Nater-Goulet, MD</td>
<td>Predictive Factors of Survival in a Surgical Series of Metastatic Epidural Spinal Cord Compression and a Complete External Validation of Eight Multivariable Scoring Systems in a Prospective North American Multi-Centre Study</td>
<td>04/30/2018 2:12-2:17 p.m.</td>
<td>Scientific Session II: Spine</td>
</tr>
<tr>
<td>Columbia Softball Pediatric Award</td>
<td>Peter Madsen, MD</td>
<td>In Silico Identification of Neo-Antigens in a High-Grade Pediatric Brain Tumor Cohort Utilizing Next-Generation Sequencing: Pilot Study of a Discovery Pipeline for Immunotherapy Targets</td>
<td>05/01/2018 4:51-5:00 p.m.</td>
<td>AANS/CNS Section on Tumors I</td>
</tr>
<tr>
<td>Mahaley Clinical Research Award</td>
<td>Ganesh Mani Shankar, MD</td>
<td>Genotype Based Local Targeted Therapy for Glioma</td>
<td>04/30/2018 3:00-3:09 p.m.</td>
<td>Scientific Session I: Tumor</td>
</tr>
<tr>
<td>Journal of Neuro-Oncology Award</td>
<td>Bob S. Carter, MD, PhD, FAANS</td>
<td>Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma who Received Yucarmale Amiretropvec and 5-Fluorocytosine Treatment</td>
<td>05/01/2018 11:32-11:42 a.m.</td>
<td>Plenary Session II</td>
</tr>
<tr>
<td>Preuss Research Award</td>
<td>Rohan Ramakrishna, MD, FAANS</td>
<td>Whole Exome and Targeted Sequencing of Adult Infiltrating Astrocytomas: Experience at a Single Institution.</td>
<td>04/30/2018 4:01-4:10 p.m.</td>
<td>Scientific Session I: Tumor</td>
</tr>
<tr>
<td>Ronald L. Bittner Award on Brain Tumor Research</td>
<td>Todd Hollon, MD</td>
<td>Convolutional Neural Networks Provide Rapid Intraoperative Diagnosis Of Neurosurgical Specimens Imaged With Stimulated Raman Histology</td>
<td>04/30/2018 3:20-3:29 p.m.</td>
<td>Scientific Session I: Tumor</td>
</tr>
<tr>
<td>AANS/CNS Joint Section on Tumors Neuro-Oncology Trainee Award</td>
<td>Amparo Myrelle Wolf, MD, PhD</td>
<td>The Risk of Malignancy after Stereotactic Radiosurgery</td>
<td>04/30/2018 4:11-4:20 p.m.</td>
<td>Scientific Session I: Tumor</td>
</tr>
</tbody>
</table>
As part of our outreach efforts, we have offered membership to those neurosurgeons who sit for the ABNS Oral Board Examination and declared Tumor as his/her subspecialty. From the May 2017 board exam, there are seven individuals who stated Tumor as their subspecialty and four of them are now Tumor Section members. From the November 2017 board exam, there were nine who stated Tumor as their subspecialty and seven are now Tumor Section Members. We welcome these new members and congratulate them on sitting for the ABNS Oral Boards!

J. Bradley Elder, MD, FAANS
Liaison to Alliance for Clinical Trials in Oncology

The AANS/CNS Tumor Section has implemented a collaboration with the Alliance for Clinical Trials in Oncology to facilitate cooperative efforts between neurosurgeons, neuro-oncologists and radiation oncologists at the national level in an effort to more efficiently support neuro-oncology clinical trials. Each issue of the Tumor Section Newsletter will highlight a clinical trial that is being sponsored by the Alliance or presented at one of the semi-annual meetings that may be of interest to neurosurgeons. Additional information regarding the Alliance is available on the website allianceforclinicaltrialsinoncology.org.

Recent report highlights:

- Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme ° PI: Evanthia Galanis, MD; Mayo Clinic
- A phase II/III randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with MGMT promoter hypermethylation ° PI: Jann Sarkaria, MD at Mayo Clinic
- Phase II trial of SMO/AKT/NF2 inhibitors in progressive meningealomas with SMO/AKT/NF2 mutations ° PI: Priscilla Brastianos, MD

The clinical trial highlighted in this report involves patients with progressive glioma and is entitled: Radiation Therapy with Concomitant and Adjuvant Temozolomide versus Radiation Therapy with Adjuvant PCV Chemotherapy in Patients with Anaplastic Glioma or Low Grade Glioma

This phase 3 clinical trial will enroll patients newly diagnosed co-deleted 1p/19q anaplastic glioma or high risk low grade glioma. Tumors must have known 1p/19q codeletion and IDH mutation. Patients who meet these and other eligibility criteria are candidates...
for one of two treatment arms:

- Arm A: Patients receive radiation therapy followed by PCV chemotherapy
- Arm B: Patients receive radiation therapy with concomitant temozolomide followed by adjuvant temozolomide

Primary objectives:
- Determine whether patients in Arm B have better progression-free survival compared to patients in Arm A
- Secondary objectives:
  - Compare toxicities of each arm
  - Determine neurocognitive and QOL effects and correlate results with outcome
  - Correlate exploratory biomarkers and survival
  - Determine whether patients in Arm B have longer time to progression (clinical or radiographic) compared to patients in Arm A

This trial is open at 231 centers in the United States and Canada. Estimated enrollment is 360 patients. The PI is Kurt Jaeckle, MD, at Mayo Clinic. Further information regarding this clinical trial can be obtained from the Alliance website at allianceforclinicaltrialsinoncology.org or clinicaltrials.gov. A list of ongoing trials sponsored by the Alliance can be accessed via the Alliance website.

The spring Alliance for Clinical Trials in Oncology meeting is May 10-12, 2018, in Chicago. For details regarding the meeting, please contact myself or Ian Parney, MD, PhD, FAANS.

Jason Sheehan, MD, PhD, FAANS

The Journal of Neuro-Oncology is the official journal of the AANS and CNS Tumor Section and is published by Springer. There are 12 regular issues and up to three supplements per year.

Journal Metrics:
- Impact factor = 2.980 for 2016
- Impact factor for 5 years = 3.046
- Number of days from submission to first decision = 58 days
- Number of days from acceptance to online publication = 12 days
- Number of publications for each of the last 3 years:
  - 2014: 348
  - 2015: 327
  - 2016: 365
- Impact factor for each of the last 3 years:
  - 2014: 3.07
  - 2015: 2.75
  - 2016: 2.98

Number of citations for each of the last 3 years:
- 2014: 8,579
- 2015: 9,092
- 2016: 9,765

Downloads for the past 3 years:
- 2014: 251,657
- 2015: 253,687
- 2016: 364,018

Special appreciation is given to the Tumor Section members who serve on the editorial board for JNO. Those on the editorial board are listed on the JNO website (http://www.springer.com/medicine/oncology/journal/11060/PS2?detailsPage=editorialBoard). For those interested in serving as a reviewer, please contact me. Also, ideas for JNO supplements and willingness to serve as an associate editor or editor for a supplement would be most appreciated. I can be reached at jsheehan@virginia.edu.
The International Committee has had a successful year, thus far, in 2018. To briefly summarize, the World Federation of Neurosurgical Societies (WFNS) has two neuro-oncology courses planned for this coming year. The European Tumor Section continues to demonstrate significant growth, achieving membership of over 200 individuals. The WFNS is also actively integrating into the AANS/CNS Tumor Section with collaborative training courses and clinical trials. The Indian Society of Neuro-Oncology has rapidly expanded their annual meetings with high attendance and plans to host a live brain tumor surgery workshop in late 2018. The Argentinean Neurosurgery Society is formalizing an exchange program for their neurosurgeons to observe in the U.S., allowing an open forum for integrated educational opportunities. This will be for three months and fully funded by Cosair Medical. The Chinese Neurosurgery Society is also planning to lead a journal issue entirely dedicated to international neurosurgery. Finally, the Federation of Latin American Neurosurgeons (FLANC) is very interested in expanding collaborations with the AANS/CNS Tumor Section. Led by Danny Prevedello, MD, this collaboration continues to expand.

---

**STEREOTACTIC RADIOSURGERY UPDATE**

Jason Sheehan, MD, PhD, FAANS

Contact: JSheehan@virginia.edu

Radiosurgical Registry Update

The AANS and ASTRO SRS registry has expanded to include 28 initiated sites from across the U.S. Thus far, over 3,000 patients have been accrued to the SRS registry. Thank you to all those who have contributed time and effort to the initiative.

Requests for access to data in the SRS registry can be submitted to the registry’s scientific board. A brief proposal regarding the data sought and the intent of the analysis is required. Several scientific studies are currently underway.

For further information, please contact Jason Sheehan at jsheehan@virginia.edu.

Radiosurgical Education and Meetings:

Upcoming radiosurgical scientific meetings include the following:

The 14th International Stereotactic Radiosurgery Society meeting will take place in Rio de Janeiro, Brazil. The meeting is June 9-13, 2019. It is hosted by Dr. Tony DeSalles. For further information, please see http://www.isrsy.org/.

Also, for those interested in SRS webinars, the ISRS has a series of SRS-focused webinars that are available for free. Further information and registration for webinars can be found at http://www.isrsy.org/en/courses/webinars/.

The SRS survey on education and training requirements has been sent out. The effort, led by Dr. Ron Warnick and assisted by Drs. Jensen, Yang, Bloch, and Sheehan with support from Dr. Kalkanis, will evaluate the current training of SRS for residents and help to identify opportunities for improvement in the same.
The 29th Annual Scientific Meeting of the North American Skull Base Society (NASBS) just wrapped up on Coronado Island, Ca. Once again, this was a record-setting meeting in all respects. Ian Witterick, MD, an otorhinolaryngologist specializing in head and neck oncology at the University of Toronto, completed his presidential year by welcoming 750 medical registrants, including practicing neurosurgeons and otorhinolaryngologists, radiation and medical oncologists, ophthalmologists, plastic and reconstructive surgeons, fellows, residents, medical students, nurse practitioners and physician assistants. Including industry support attendees, nearly 900 people participated in the scientific and social programs. The society welcomed 121 new members this past year.

The theme of the meeting was Dynamic mentoring of the skull base surgeon: Training our future. Directly addressing this important topic, honored guests Dr. Patrick Gullane (otorhinolaryngology), Dr. Fred Gentilli (neurosurgery) and Dr. Peter Neligan (plastic and reconstructive surgery) gave insightful addresses about their cumulative experience over the last three decades shepherding the next generation of leaders in skull base surgery. Dr. Harry van Loveren, professor and chairman of neurosurgery at University of South Florida in Tampa gave a very practical and thoughtful address about the “10 rules” of surgical mentorship.

The remainder of the program was packed with expert debate panels, special topic sessions, proffered papers and posters addressing every aspect of the diagnosis and management of skull base disorders. As usual, there was a 2-day, pre-meeting, hands-on practical dissection course, this year held at the UCSD practical lab, that sold out and received rave reviews from participants. Also, the day before the meeting opened, there was a symposium specially dedicated to the management of meningioma, with experts in the field of surgery, radiation and molecular biology providing an extremely informative and thought-provoking one-day focused overview. There were several unique and new sessions during this year’s meeting. There was a special “Rhoton room,” dedicated to the incredible legacy of Albert L. Rhoton Jr., MD, FAANS(L), and his contribution to surgical anatomy and skull base tumors in particular. There were expert 3-D anatomy presentations by his former fellows and dueling dissections in which two different teams performed live cadaveric dissections to demonstrate various open and endoscopic skull base approaches with commentary and moderation provided by the true giants in the field. The top ten submitted scientific abstracts were selected for a “three-minute thesis,” in which the presenting author is allowed one slide and three minutes to explain their research in a judged competition. In addition, there was a special session dedicated to women in skull base surgery. Finally, the last day of the meeting addressed pituitary tumor diagnosis and non-surgical and surgical management.

James Evans, MD, FAANS, professor of neurosurgery at Thomas Jefferson University in Philadelphia was elected President of the NASBS for the upcoming year. He is already well into planning a very dynamic meeting for February 15-17, 2019, at the Hilton Orlando Bonnet Creek Hotel, in Orlando. A special full-day symposium regarding the diagnosis and management of pituitary tumors is planned for February 14, 2019. If you are interested in participating in any aspect of the 30th annual scientific meeting of the NASBS, please contact Jim at (james.evans@jefferson.edu) or the scientific program co-chairs, Dr. Amir Dehdashti (adehdashti@northwell.edu) and Dr. Adam Zanation (adam.zanation@med.unc.edu). Also, be sure to note that if you have residents or fellows that would like more hands on experience with complex endoscopic and open skull base approaches, the NASBS summer practical course will be held July 26-29, 2018, at LSU Health Sciences center in New Orleans. All details can be found at www.NASBS.org.

Looking forward to seeing everyone at the Tumor Section events at the 2018 AANS Annual Scientific Meeting in New Orleans in April/May.
Boston – Russell R. Lonser, MD, FAANS, professor and chair of neurosurgery at Ohio State University and former president of the CNS, was the honored guest at the AANS/CNS Section on Tumors Young Neurosurgeons Reception, co-hosted by the Young Neurosurgeons Committee, at the CNS Annual Meeting on October 10, 2017.

A national recognized neurosurgeon and researcher, Dr. Lonser addressed over 75 young neurosurgeons and leaders of the tumor section on the current state, challenges and opportunities available to neurosurgeon-scientists early in their career. He began his lecture by discussing the current challenges facing research scientists attempting to balance their scientific aspirations with the need for clinical productivity, including the apparent decrease in total research funding. Despite these roadblocks, he surprised many in the audience by highlighting recently published data illustrating the progressively increased number of patents and publications from neurosurgeons over the past 20 years. Additionally, given his experience, he educated the group on the funding timeline early neurosurgeon-researchers could take within the NIH, working from early investigator opportunities like R25 and K12 grants to the ultimate goal of many in attaining an R01 grant. Through his journey down the funding timeline, he emphasized the importance of the young neurosurgeon's first five years in practice. He ultimately appeared to quell the concerns of many in the audience striving to develop a research career by illustrating various models one could take to attain research success and highlighting the fact that funding and research opportunities are actually greater now than ever within neurosurgery.

The AANS/CNS Section on Tumors and the Young Neurosurgeons Committee are pleased to announce that the honored guest for the Young Neurosurgeons Reception at the 2018 AANS Annual Scientific Meeting (Tuesday, May 1st from 6:15 to 8:15 p.m.) is the new chairman of the department of neurosurgery at the MD Anderson Cancer Center, Frederick Lang, MD, FAANS.
The prolific work of the Tumor Section on guidelines provided a significant impact at the recent annual CNS meeting in Boston. This included a training course entitled “A Primer on the Development and Review of Evidence-Based Clinical Guidelines” for new and prospective members of the Joint Guidelines Committee to understand how to review guidelines from throughout the specialty. The Tumor Section provided multiple speakers for this course in view of our member’s extensive experience with this topic.

There was also a “Guidelines on Brain Tumors Update” presented by our members involved in the guidelines creation for non-functioning pituitary adenomas, low grade gliomas, vestibular schwannomas and metastatic brain tumors.

Vestibular Schwannoma Management Guidelines
This guideline was published electronically in the December 2017 issue of Neurosurgery and is available in hard copy. It is now available in the CNS Guidelines Application.

Metastatic Brain Tumor Management Guidelines Update
This 9-part guideline is now in the second round of Joint Guidelines Review Committee for review. We are working with ASTRO, ASCO, SNO and Cancer Care Ontario to obtain their endorsements and their assistance in disseminating these guidelines to all five societies.

Newly Diagnosed Glioblastoma Management Guidelines Update
The manuscripts for this have been completed and are pending submission to the Joint Guidelines Review Committee for review with the goal of publication in Journal of Neuro-Oncology, as were the original guidelines published on this topic.

Metastatic Spine Tumor Management Guidelines
A first set of manuscripts for these guidelines have been completed and are pending submission to the Joint Guidelines Review Committee, with the goal of being published in Neurosurgery.

The Guidelines Committee remains open to new ideas and projects:

1. For those that wish assistance by the CNS Guidelines Office, there is a formal application form that can be obtained from Trish Rehring in the CNS Guidelines Office via the CNS website. Once completed, it can be returned for consideration – first by the Joint Tumor Section Guidelines Committee and then by the CNS Guidelines Committee, where it is prioritized for development, particularly if CNS resources are requested to assist in their construction. The Tumor Section Guidelines Committee can then serve as consultants for the writers at whatever level is necessary to assist in completion.

2. Alternatively, for those who wish to develop a guideline independently, allowing greater latitude in publication options, the Joint Tumor Section Guidelines Committee can provide step-by-step instruction and critique to create a quality product for Joint Guidelines Review Committee submission.
AANS/CNS Section on Tumors Executive Committee Update

Chair 2016 - 2018: Steven Kalkanis
Secretary-Treasurer: Manish Aghi
Past Chair; Nominating: Fred Barker

Advisory Board
Fred Lang
Gene Barnett
Mitchel Berger
Jeff Bruce
Robertta Glick
Jim Markert
Mark Rosenblum
James Rutka
Michael McDermott
Peter Black
William Coulldwell
Ron Warnick
Ennio Chiocca

Awards : Isabelle Germano
Bylaws: Jason Heth
Clinical Trials - Chair: Michael Vogelbaum
Clinical Trials - ABTC: Andy Sloan
Clinical Trials - Alliance: Brad Elder
Clinical Trials - NRG: Dan Cahill
Communications/IT/Website - Chair: Jeff Weinberg
Communications/IT/Website - Social Media: Edjah Nduom
Communications/IT/Website
Adam Sonabend
Pierpaolo Peruzzi
Dimitris Placantonakis
Development - Co-Chair
Will Curry
Allen Waziri

Development
Orin Bloch
Chris Farrell
Ian Dunn
Michael Lim
Brian Nahed
Nader Sanai
Isaac Yang

Education - Scientific Program Chair: Jason Sheehan
Education - Continuing/Practice Assessment Chair: Costas Hadjipanayis
Guidelines - Chair
Jeff Olson
Brian Nahed

Guidelines
Timothy Ryken
Ian Dunn
Gavin Dunn
Gabriel Zada

History: Tony D’Ambrosio
Immunotherapy: Ian Parney
International - Chair: Rick Komotar
International -Vice Chair (Europe): Ekkehard Kasper
International- Vice Chair (Asia): Clark Chen

International - WFNS Liaison: Gelarch Zadeh
International - Advisor: Isabelle Germano
International - EANS
Zvi Ram
Colin Watts
International - Argentina: Alejandra Rabadan
International - Australia: Charlie Teo
International - Central America: Jose Valerio
International - India: Atul Goel
International - Pakistan (South Asia liaison): S. Ather Enam
International - Italy: Francesco Dimeco
International - Germany: Manfred Westphal
International - England: S George amandouras
International - Japan: Fumio Yamaguchi
International - Nigeria (Africa Liaison): Okezie Obasi Kanu
International - Switzerland: Dominik Cordier
International - Turkey: Ugur Ture
International - AANS Ambassador for AANSNS: Clark Chen
International - AANS Ambassador for CAANS: Brian Nahed
International - AANS Ambassador for EANS: Michael McDermott
International - AANS Ambassador for EANS: Fred Barker
International - AANS Ambassador for FLANC: Danny Prevedello
Journal of Neuro-oncology (Editor): Linda Liu
MATRiX and CAST: Ennio Chiocca
Medical Neuro-Oncology: Susan Chang
Membership - Chair: Jen Moliterno Gunel
Membership - Vice Chair: Edjah Nduom
Member Services and Outreach - Chair: Randy Jensen
Member Services - Mentor/Job Match: Gavin Dunn
Member Services- East Coast Membership Director: Edjah Nduom
Member Services-Midwest Membership Director: Brad Elder
Member Services-West Coast Membership Director: Gabriel Zada
Newsletter- Editor: Ian Lee
Newsletter - Assistant Editor: Pamela Jones
NeuroPoint Alliance/Outcomes - Co-Chair
Mark Linskey
Brad Elder

NeuroPoint Alliance/Outcomes: Timothy Smith
Pediatrics: Paul Klimo
Prize Stewardship - Chair: Andy Sloan
Prize Stewardship
Orin Bloch
Tony D’Ambrosio
Program Chair - Satellite 2016
Chetan Bettexowda
Brian Nahed
Program Chair - AANS 2017
Peter Feci
Shawn Hervey-Jumper
Program Chair - CNS 2017
Pamela Jones
Adam Robin
Program Chair - AANS 2018
Wajd Al-Hallou
Rohan Ramakrishna
Program Chair - CNS 2018
Seungu Han
Gordon Li
Program Advisory Committee
John Kuo
Michael Sughrue
Ian Dunn
Jonathan Sherman
Matthew Tate

Radiosurgery: Jason Sheehan
Research/ Parsa Fellowship - Chair: Orin Bloch
Research/ Parsa Fellowship
Brad Elder
Daniel Orringer
Research/ Rutka Fellowship - Co-Chair
John Kuo
Gelarch Zadeh
SANS - Chair: Sarah Jost Fouke
SANS: Viviane Tabar
SANS - Board Member representative
Michael McDermott
Nader Sanai

Simulation & Technology: Aaron Cohen-Gadol
Skull Base - Co-Chair
Michael Link
Danny Prevedello

SNO Liaison
Gelarch Zadeh
SNS Liaison:
Mark Linskey
Spine - Chair: Larry Rhines
Spine: Nicholas Szerlip
Washington Committee - Chair: Brian Nahed

WINS - Liaison: Analiz Rodriguez
Young Neurosurgeons - Chair: Walavan Sivakumar
Young Neurosurgeons - Vice Chair: Brian Howard